INmune Bio, Inc. (INMB)
NASDAQ: INMB · IEX Real-Time Price · USD
10.62
+0.48 (4.73%)
At close: Apr 24, 2024, 4:00 PM
10.65
+0.03 (0.28%)
After-hours: Apr 24, 2024, 7:36 PM EDT
INmune Bio Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for INmune Bio stock has a target of 16, which predicts an increase of 50.66% from the current stock price of 10.62.
Analyst Consensus: Buy
* Price targets were last updated on Jun 1, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for INmune Bio is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 | Jun '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Initiates $16 | Buy | Initiates | $16 | +50.66% | Jun 1, 2023 |
| BTIG | BTIG | Strong Buy Maintains $31 → $14 | Strong Buy | Maintains | $31 → $14 | +31.83% | May 24, 2022 |
| B. Riley Securities | B. Riley Securities | Strong Buy → Hold Downgrades $14 → $7 | Strong Buy → Hold | Downgrades | $14 → $7 | -34.09% | May 24, 2022 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $32 → $20 | Strong Buy | Maintains | $32 → $20 | +88.32% | Jan 24, 2022 |
| BTIG | BTIG | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Sep 1, 2020 |
Financial Forecast
Revenue This Year
112.20K
from 155.00K
Decreased by -27.61%
Revenue Next Year
122.40K
from 112.20K
Increased by 9.09%
EPS This Year
-2.24
from -1.67
EPS Next Year
-1.99
from -2.24
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 115,500 | 126,000 | 126,000 | 192.0M | 318.1M |
| Avg | 112,200 | 122,400 | 122,400 | 93.3M | 161.1M |
| Low | 107,800 | 117,600 | 117,600 | 184,240 | 12.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -25.5% | 12.3% | 2.9% | 156,721.9% | 240.8% |
| Avg | -27.6% | 9.1% | - | 76,149.2% | 72.6% |
| Low | -30.5% | 4.8% | -3.9% | 50.5% | -86.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.79 | -1.91 | -1.93 | 5.92 | 11.03 |
| Avg | -2.24 | -1.99 | -1.90 | 1.84 | 4.52 |
| Low | -2.40 | -2.05 | -1.85 | -1.99 | -1.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 498.8% |
| Avg | - | - | - | - | 145.4% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.